FGF2 and abdominal aortic aneurysm: In vivo targeting of Nudt6 (which is an antisense transcript of fibroblast growth factor 2; FGF2) with ASO, using murine and porcine models of carotid artery disease and abdominal aortic aneurysm, showed limited disease progression [163].